These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37795027)

  • 1. Ocular development after highly effective modulator treatment early in life.
    Zhu Y; Li D; Reyes-Ortega F; Chinnery HR; Schneider-Futschik EK
    Front Pharmacol; 2023; 14():1265138. PubMed ID: 37795027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.
    Caverly LJ; Riquelme SA; Hisert KB
    Clin Chest Med; 2022 Dec; 43(4):647-665. PubMed ID: 36344072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.
    Stekolchik E; Saul D; Chidekel A
    Respir Med Case Rep; 2022; 40():101775. PubMed ID: 36411821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CFTR Modulators: Current Status and Evolving Knowledge.
    Regard L; Martin C; Da Silva J; Burgel PR
    Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A grumbling concern: an international survey of gastrointestinal symptoms in cystic fibrosis in the modulator era.
    Calthorpe RJ; Goodchild N; Gleetus V; Premakumar V; Hayee B; Elliott Z; Evans B; Rowbotham NJ; Carr SB; Barr H; Horsley A; Peckham D; Smyth AR
    NIHR Open Res; 2023; 3():18. PubMed ID: 37881465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.
    Westhölter D; Raspe J; Uebner H; Pipping J; Schmitz M; Straßburg S; Sutharsan S; Welsner M; Taube C; Reuter S
    Front Immunol; 2023; 14():1107437. PubMed ID: 36875141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    O'Carroll M
    Semin Respir Crit Care Med; 2023 Apr; 44(2):260-268. PubMed ID: 36893762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in cystic fibrosis decreases after initiation of highly effective CFTR modulator therapy.
    Eschenhagen PN; Bacher P; Grehn C; Mainz JG; Scheffold A; Schwarz C
    Front Pharmacol; 2023; 14():1180826. PubMed ID: 37408761
    [No Abstract]   [Full Text] [Related]  

  • 9. Airway clearance after highly effective CFTR modulators: Normalizing life and reducing treatment burden.
    Goetz DM; Frederick CK; Perez G; Borowitz D
    Pediatr Pulmonol; 2023 Aug; 58(8):2375-2380. PubMed ID: 37232336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis.
    Gómez-Montes E; Salcedo Lobato E; Galindo Izquierdo A; García Alcázar D; Villalain González C; Moral-Pumarega MT; Bustos Lozano G; Luna-Paredes C
    Fetal Diagn Ther; 2023; 50(2):136-142. PubMed ID: 36996799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor.
    Tsai A; Wu SP; Haseltine E; Kumar S; Moskowitz SM; Panorchan P; Shah K
    Pulm Ther; 2020 Dec; 6(2):275-286. PubMed ID: 32734574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding.
    Jain R; Wolf A; Molad M; Taylor-Cousar J; Esther CR; Shteinberg M
    J Cyst Fibros; 2022 Nov; 21(6):1074-1076. PubMed ID: 36266182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.
    Middleton PG; Taylor-Cousar JL
    Expert Rev Respir Med; 2021 Jun; 15(6):723-735. PubMed ID: 33249928
    [No Abstract]   [Full Text] [Related]  

  • 15. Challenges in the use of highly effective modulator treatment for cystic fibrosis.
    Ramos KJ; Pilewski JM; Taylor-Cousar JL
    J Cyst Fibros; 2021 May; 20(3):381-387. PubMed ID: 33531206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis.
    Beswick DM; Liu CM; Overdevest JB; Zemke A; Khatiwada A; Gudis DA; Miller JE; Kimple A; Tervo JP; DiMango E; Goralski JL; Keating C; Senior B; Stapleton AL; Eshaghian PH; Mace JC; Markarian K; Alt JA; Bodner TE; Chowdhury NI; Getz AE; Hwang PH; Khanwalker A; Lee JT; Li DA; Norris M; Nayak JV; Owens C; Patel ZM; Poch K; Schlosser RJ; Smith KA; Smith TL; Soler ZM; Suh JD; Turner GA; Wang MB; Saavedra MT; Taylor Cousar JL
    Laryngoscope; 2024 Apr; ():. PubMed ID: 38634358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies.
    Desai M; Hine C; Whitehouse JL; Brownlee K; Charman SC; Nagakumar P
    Respir Med; 2022 Aug; 199():106878. PubMed ID: 35633605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.
    Jordan KD; Zemanick ET; Taylor-Cousar JL; Hoppe JE
    Expert Rev Respir Med; 2023 Feb; 17(2):97-108. PubMed ID: 36803356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.